Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Thomas

Showing results (151-160 of 262) with videos related to

Pageof 27
Sort By:
Haematologica|February 24, 2018
Clinical relevance of <i>IDH1/2</i> mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA groupYann Ferret, Nicolas Boissel, Nathalie Helevaut, et al.
Cancers|April 25, 2019
Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution ExperienceMaël Heiblig, Hélène Labussière-Wallet, Franck Emmanuel Nicolini, et al.
Leukemia & Lymphoma|November 6, 2020
Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adultsMarie-Anne Couturier, Xavier Thomas, Emmanuel Raffoux, et al.
Neoplasia (New York, N.Y.)|February 25, 2014
Chromatin redistribution of the DEK oncoprotein represses hTERT transcription in leukemiasMaroun Karam, Morgan Thenoz, Valérie Capraro, et al.
Blood|August 28, 2009
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapseFrancis Giles, Norbert Vey, Daniel DeAngelo, et al.
Leukemia & Lymphoma|November 22, 2013
A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction courseDavid Rizzieri, Norbert Vey, Xavier Thomas, et al.
Blood Cancer Journal|June 13, 2024
Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA studyPierre Hirsch, Jérôme Lambert, Maxime Bucci, et al.
Leukemia & Lymphoma|June 9, 2020
Ponatinib-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the real-life OPAL studySuzanne Tavitian, Madalina Uzunov, Emilie Bérard, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 30, 2004
Rescue therapy combining intermediate-dose cytarabine with amsacrine and etoposide in relapsed adult acute lymphoblastic leukemiaOumedaly Reman, Agnes Buzyn, Veronique Lhéritier, et al.
Plos One|December 20, 2012
High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemiaSandrine Hayette, Xavier Thomas, Laurent Jallades, et al.
Pageof 27

Showing results (151-160 of 262) with videos related to

Sort By:
Pageof 27
Haematologica|February 24, 2018
Clinical relevance of <i>IDH1/2</i> mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA groupYann Ferret, Nicolas Boissel, Nathalie Helevaut, et al.
Cancers|April 25, 2019
Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution ExperienceMaël Heiblig, Hélène Labussière-Wallet, Franck Emmanuel Nicolini, et al.
Leukemia & Lymphoma|November 6, 2020
Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adultsMarie-Anne Couturier, Xavier Thomas, Emmanuel Raffoux, et al.
Neoplasia (New York, N.Y.)|February 25, 2014
Chromatin redistribution of the DEK oncoprotein represses hTERT transcription in leukemiasMaroun Karam, Morgan Thenoz, Valérie Capraro, et al.
Blood|August 28, 2009
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapseFrancis Giles, Norbert Vey, Daniel DeAngelo, et al.
Leukemia & Lymphoma|November 22, 2013
A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction courseDavid Rizzieri, Norbert Vey, Xavier Thomas, et al.
Blood Cancer Journal|June 13, 2024
Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA studyPierre Hirsch, Jérôme Lambert, Maxime Bucci, et al.
Leukemia & Lymphoma|June 9, 2020
Ponatinib-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the real-life OPAL studySuzanne Tavitian, Madalina Uzunov, Emilie Bérard, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 30, 2004
Rescue therapy combining intermediate-dose cytarabine with amsacrine and etoposide in relapsed adult acute lymphoblastic leukemiaOumedaly Reman, Agnes Buzyn, Veronique Lhéritier, et al.
Plos One|December 20, 2012
High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemiaSandrine Hayette, Xavier Thomas, Laurent Jallades, et al.
Pageof 27